Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PharmaTher Holdings Ltd ( (TSE:PHRM) ) has shared an update.
PharmaTher Holdings Ltd. announced the strategic sale of its Abbreviated New Drug Application for Ketamine Hydrochloride Injection USP, a move designed to provide non-dilutive capital and leverage the expertise of a global pharmaceutical partner. This transaction allows PharmaTher to focus on its broader ketamine-based programs, including treatments for Parkinson’s disease, ALS, and CRPS, while pursuing international partnerships and regulatory engagements to expedite clinical paths and commercialization efforts.
Spark’s Take on TSE:PHRM Stock
According to Spark, TipRanks’ AI Analyst, TSE:PHRM is a Neutral.
PharmaTher Holdings Ltd. faces substantial financial hurdles, with no revenue and persistent losses weighing heavily on its stock score. However, recent positive corporate developments regarding FDA approval for ketamine could provide a significant future boost. Technical indicators are currently neutral, and valuation metrics reflect typical challenges for biotech firms in early stages. The potential regulatory approval is a key factor for future growth, but immediate financial struggles limit the current score.
To see Spark’s full report on TSE:PHRM stock, click here.
More about PharmaTher Holdings Ltd
PharmaTher Holdings Ltd. is a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine for mental health, pain, and neurological disorders.
Average Trading Volume: 269,564
Technical Sentiment Signal: Buy
Current Market Cap: C$17.26M
See more insights into PHRM stock on TipRanks’ Stock Analysis page.